Animal Model Market Report 2026

The animal model market size has grown strongly in recent years. It will grow from $2.07 billion in 2025 to $2.24 billion in 2026 at a compound annual growth rate (CAGR) of 8.5%. The growth in the historic period can be attributed to increasing prevalence of chronic diseases, rising demand for preclinical research, growth in pharmaceutical r&d, technological advancements in laboratory equipment, expansion of academic research institutions.

The animal model market size is expected to see strong growth in the next few years. It will grow to $2.97 billion in 2030 at a compound annual growth rate (CAGR) of 7.3%. The growth in the forecast period can be attributed to adoption of ai and machine learning in preclinical studies, rise of precision medicine initiatives, growth of crcos and outsourcing, expansion of genetically modified animal models, increased focus on translational research. Major trends in the forecast period include advanced animal model development, genetically engineered models, high-throughput screening in preclinical studies, integration of imaging and diagnostic tools, expansion of contract research organizations.

The increasing investment in pharmaceutical research and development (R&D) is anticipated to drive the growth of the animal model market in the coming years. Pharmaceutical R&D encompasses the discovery, development, and testing of new therapies, requiring comprehensive preclinical studies to assess safety, efficacy, and biological mechanisms before progressing to human trials. The rise in R&D spending is fueled by the growing demand for innovative treatments, the increasing prevalence of complex diseases, and ongoing scientific advancements. Animal models serve a vital role in this process by offering reliable preclinical platforms that replicate human physiology, allowing for predictive evaluation of drug performance. For example, in November 2023, a report published by the European Federation of Pharmaceutical Industries and Associations, a Belgium-based trade association, indicated that pharmaceutical industry R&D expenditure increased to 50.0 billion in 2023, up from 47.01 billion in 2022. Thus, the rising pharmaceutical R&D investment is contributing to the growth of the animal model market.

Major companies operating in the animal model market are emphasizing the development of innovative products, such as triple-immunodeficient animal models, to improve the accuracy and reliability of preclinical studies, support advanced biomedical research, and aid in the creation of novel therapies for complex human diseases. Triple-immunodeficient animal models are specially engineered animals, usually mice, that lack three critical components of the immune system. These models are highly valuable in biomedical research, especially for investigating human diseases and developing new treatments. For example, in January 2024, Charles River Laboratories International, Inc., a US-based pharmaceutical company, introduced NCG mouse strains, a triple-immunodeficient mouse model designed for oncology research. NCG mice are triple immunodeficient, missing functional/mature T, B, and NK cells, and show reduced macrophage and dendritic cell activity. These animal models can accommodate xenograft cells, tissues, and human immune system elements. This mouse model is suitable for research in oncology, immunology, tumor biology, infectious diseases, graft-versus-host disease (GvHD), diabetes, regenerative medicine, hematopoiesis, and tissue transplant studies. NCG mice can also be used to generate humanized mice by engrafting PBMCs or CD34+ stem cells, closely replicating the human immune system.

In May 2024, The Jackson Laboratory, a US-based non-profit biomedical research organization providing animal models, formed a partnership with AbTherx Inc. to develop advanced preclinical models for testing novel therapeutics. Through this collaboration, The Jackson Laboratory aims to enhance and expedite antibody discovery efforts by combining its advanced preclinical models and translational research expertise with AbTherx’s next-generation antibody engineering platform. AbTherx Inc. is a US-based biotechnology company focused on innovative antibody discovery technologies designed to streamline and reduce risks in therapeutic development.

Major companies operating in the animal model market are Eurofins Scientific SE, Charles River Laboratories International Inc., Pharmaron Beijing Co Ltd, Inotiv Inc., Biocytogen, Taconic Biosciences Incorporation, Cyagen Biosciences, Trans Genic Incorporation, Crown Bioscience Incorporation, Harbor BioMed, PharmaLegacy, PsychoGenics, Biomere Biomedical Research Models Inc., Genoway S.A, Alloy Therapeutics, Janvier Labs, Hera Biolabs, Ozgene Pty Ltd, Transposagen Biopharmaceuticals Inc., KMT Hepatech Inc., AniLocus Inc., BioXpert, Harlan Sprague Dawley Inc.

North America was the largest region in the animal model market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the animal model market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the animal model market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have affected the animal model market by increasing the cost of importing laboratory animals, genetically engineered models, and specialized equipment. The drug discovery and basic research segments are most impacted, particularly in North America, Europe, and Asia-Pacific regions like China and India, which are key suppliers and users of animal models. While tariffs have raised operational costs and slowed procurement, some manufacturers are exploring local breeding programs and regional sourcing, potentially strengthening domestic capabilities and reducing long-term dependency on imports.

The animal model market research report is one of a series of new reports that provides animal model market statistics, including animal model industry global market size, regional shares, competitors with a animal model market share, detailed animal model market segments, market trends and opportunities, and any further data you may need to thrive in the animal model industry. This animal model market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

An animal model is a non-human species utilized in scientific research to explore biological processes, investigate disease mechanisms, and assess the effectiveness and safety of new treatments and interventions. These models enable researchers to expand medical knowledge and create new therapies, bridging the gap between fundamental research and clinical application.

The main types of animal models include mice, rats, guinea pigs, rabbits, hamsters, and others. Mice are small rodents from the family Muridae, generally distinguished by a pointed snout, rounded ears, and long, hairless tails. The technologies include clustered regularly interspaced short palindromic repeats (CRISPR), embryonic stem cell injection, nuclear transfer, and others, and they are applied in areas such as drug discovery and development, basic research, and others. The end users of animal models are research institutes, educational institutes, pharmaceutical companies, and contract research organizations.

The animal model market consists of revenues earned by entities by providing services custom animal model development, animal breeding and colony management, behavioral and neurological testing, and surgical services. The market value includes the value of related goods sold by the service provider or included within the service offering. The animal model market consists of sales of genetically engineered models, spontaneous models, induced models, xenograft and allograft models, and environmental models. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.